Datavault AI has granted Scilex Holding Company an exclusive worldwide license to deploy its proprietary AI-driven technology within the biotech and biopharma sectors. The agreement enables Scilex to build and operate a Biotech Exchange platform to tokenize, trade, and monetize biotech assets such as genomic data, diagnostics, and drug information. This strategic partnership represents a significant step toward transforming how biotech assets are valued and exchanged in digital markets.
The financial terms of the agreement include a $10 million upfront payment in four installments and up to $2.55 billion in potential milestone payments. This substantial financial commitment reflects the anticipated value of the technology in addressing what Datavault AI estimates as a $2 trillion market opportunity. The technology is expected to expand beyond biotech into a comprehensive Pharmaceutical Exchange platform, providing companies with new pathways to access non-dilutive funding.
Datavault AI's technology leverages blockchain solutions for data monetization and asset tokenization, supported by the company's broad patent portfolio and proven high-performance computing expertise. The platform's capabilities extend to the Information Data Exchange, which enables Digital Twins and licensing of name, image, and likeness by securely attaching physical real-world objects to immutable metadata objects. This approach fosters responsible AI with integrity while creating new monetization opportunities.
The company's cloud-based platform provides comprehensive solutions serving multiple industries, including HPC software licensing for sports & entertainment, events & venues, biotech, education, fintech, real estate, healthcare, energy and more. The technology suite is completely customizable and offers AI and Machine Learning automation, third-party integration, detailed analytics and data, marketing automation and advertising monitoring. Additional information about Datavault AI's technology can be found at https://www.datavaultsite.com.
This licensing agreement represents a significant validation of Datavault AI's approach to asset tokenization and data monetization in the Web 3.0 environment. The biotech sector's adoption of this technology could revolutionize how valuable research data, diagnostic information, and pharmaceutical assets are traded and monetized globally. The platform's ability to provide secure, transparent exchange mechanisms for traditionally illiquid assets positions it as a potential game-changer in biotech financing and asset management.
